Institute for Ethics and Emerging Technologies

The IEET is a 501(c)3 non-profit, tax-exempt organization registered in the State of Connecticut in the United States. Please give as you are able, and help support our work for a brighter future.

Search the IEET
Subscribe and Contribute to:

Technoprogressive? BioConservative? Huh?
Quick overview of biopolitical points of view

whats new at ieet

Technology hasn’t changed love. Here’s why

Why Non-Natural Moral Realism is Better than Divine Command Theory

IEET Affiliate Scholar Steve Fuller Publishes New Article in The Telegraph on AI

Can we build AI without losing control over it?

Blockchain Fintech: Programmable Risk and Securities as a Service

Brexit for Transhumanists: A Parable for Getting What You Wish For

ieet books

Philosophical Ethics: Theory and Practice
John G Messerly


spud100 on 'For the unexpected innovations, look where you'd rather not' (Oct 22, 2016)

spud100 on 'Have you ever inspired the greatest villain in history? I did, apparently' (Oct 22, 2016)

RJP8915 on 'Brexit for Transhumanists: A Parable for Getting What You Wish For' (Oct 21, 2016)

instamatic on 'What democracy’s future shouldn’t be' (Oct 20, 2016)

instamatic on 'Is the internet killing democracy?' (Oct 17, 2016)

RJP8915 on 'The Ethics of a Simulated Universe' (Oct 17, 2016)

Nicholsp03 on 'The Ethics of a Simulated Universe' (Oct 17, 2016)

Subscribe to IEET News Lists

Daily News Feed

Longevity Dividend List

Catastrophic Risks List

Biopolitics of Popular Culture List

Technoprogressive List

Trans-Spirit List


Enframing the Flesh: Heidegger, Transhumanism, and the Body as “Standing Reserve”

Moral Enhancement and Political Realism

Intelligent Technologies and Lost Life

Hottest Articles of the Last Month

Here’s Why The IoT Is Already Bigger Than You Realize
Sep 26, 2016
(5983) Hits
(1) Comments

IEET Fellow Stefan Sorgner to discuss most recent monograph with theologian Prof. Friedrich Graf
Oct 3, 2016
(4076) Hits
(0) Comments

Space Exploration, Alien Life, and the Future of Humanity
Oct 4, 2016
(4006) Hits
(1) Comments

Blockchain Fintech: Programmable Risk and Securities as a Service
Oct 22, 2016
(3274) Hits
(0) Comments

IEET > Security > Biosecurity > Rights > Life > Access > Innovation > Health > Vision > Bioculture > Contributors > Andrew Maynard

Print Email permalink (2) Comments (23944) Hits •  subscribe Share on facebook Stumble This submit to reddit submit to digg

Is using nano silver to treat Ebola misguided?

Andrew Maynard
By Andrew Maynard
Risk Science

Posted: Aug 16, 2014

On Thursday this week, the Wall Street Journal reported that Ebola victims in Nigeria’s commercial capital Lagos will receive Nano Silver in an attempt to treat the infection.  The news comes hot on the heels of the World Health Organization’s decision to sanction the use of unlicensed Ebola drugs in West Africa on ethical grounds.  It also coincides with a US Food and Drug Administration statement released yesterday warning against fraudulent Ebola treatment products.

Is the use of nano silver a legitimate application of on unlicensed treatment, or cynical exploitation of a mounting humanitarian crisis?  Having studied and written about the biological impacts of nano silver for some years now, I must confess I was surprised by the Nigerian decision.

Silver as an antimicrobial

Silver has been used as an antimicrobial agent for thousands of years – the Romans used to use silverware to reduce food and drink-borne infection.  More recently, nanoparticles of silver have been used in everything from food containers to socks in an attempt to imbue them with microbe-killing properties.

When used in the right way, the material certainly does exhibit antimicrobial properties.  But there’s a massive jump from odor-resistant socks to curing Ebola patients.

An Open Letter on Ebola Treatment to Nigeria’s President

The Nigerian decision to treat patients with nano silver seems to stem from an open letter to President Goodluck Jonathan from one Dr Rima E. Laibow.

As Dr. Laibow writes in her letter,

“There is, in fact, a well-established, non-toxic anti-microbial, without any known side effects, available at remarkably low cost which – • Requires no refrigeration • Is self-sterilizing. • Is readily available • Has a very long shelf life • Is not subject to degradation under temperature and humidity extremes. That nutrient substance is Nano Silver.”

Dr.  Laibow is Medical Director of an organization called the Natural Solutions Foundation.  And one of the products this organization sells is  colloidal nano silver.

Colloidal Nano Silver

Colloidal nano silver – nanometer-sized silver particles suspended in water – has been used by people to self-medicate innumerable conditions for around a century now.  Although there is no clear evidence that it has beneficial health effect at low concentrations, it can cause the disease argyria at high concentrations.

Nano silver has been on the radar of researchers and regulators for over a decade now as a substance that may be more toxic than originally thought.  As a result, there has been an intense global research effort into its human and ecological toxicity in recent years.  Studies have shown that nanoscale silver particles can be harmful if released into the environment in large quantities, and may possibly cause harm in unexpected ways in the human body under specific circumstances.  Yet there’s been little published on the use of nano silver as a treatment for infectious diseases.

Despite this, Dr. Laibow writes on the Natural Solutions Marketplace website:

That is why we can say with confidence that Dr. Rima Recommends™ The Silver Solution (Nano Silver 10 PPM) has been shown to deal effectively with the Ebola virus.

In fact, every disease causing organism against which it has been tested, all around the world has been killed (bacteria, parasites) or inactivated (viruses) by this amazing solution.

How much do you need for yourself and your loved ones? Enter your email information and I will send you my Professional Protocol as my gift to you.

US Government Research on Nano Silver and Ebola

The source of Dr. Laibow’s optimism appears to be a 2009 presentation of research carried out by Janice Speshock and Saber Hussain at the US Air Force National Laboratory.  A Powerpoint of this presentation has been declassified, and is currently doing the rounds on the internet.

The presentation reports on research into the effectiveness of silver nanoparticles in rendering hemorrhagic fever viruses like Ebola ineffective.  The study was carried out using cell cultures, and a number of viruses and virus-like particles.  It seemed to indicate that when the silver nanoparticles penetrated into cells along with the virus in sufficient quantities, they were effective at preventing the virus from being active once the cell had been exposed.

While it is impossible to interpret research findings from Powerpoint slides alone, the data do suggest that there are some unusual interactions between silver nanoparticles and Ebola-like viruses, although there are no data indicating whether similar interactions are also seen with other nanoparticles.  More importantly, they do not indicate whether these same interactions would occur in an infected patient.  They also do not indicate the quantity of silver nanoparticles someone wold need to take to render Ebola ineffective, or whether the necessary dose to have an effect would cause medical complications.

This presentation builds on previously published research by Speshock and Hussain that looked at Monkey Pox virus plaque formation inhibition by nano silver.  Using cell cultures, the researchers found that nano silver and and silver ions were effective at reducing Monkey Pox Virus-induced plaques.  However, they also concluded

“The present study demonstrates the feasibility of implementing the use, and characterizing the efficacy, of silver-based nanoparticles against [Monkey Pox Virus] infection in vitro. However, for nanoparticles to be used in therapeutic or prophylactic treatment regimens, it is critical to understand the in vivo toxicity and potential for long-term sequelae associated with exposure to these compounds.”

In 2010 Speshock and Hussain published research on the interaction of silver nanoparticles with Tacaribe virus.  The research – published in the Journal of Nanobiotechnology – indicated that in cell cultures, the presence of silver nanoparticles increased the cell uptake of the virus, but also suppressed its activity once in cells.  They concluded

“Due to the known toxicity of Ag- NPs [silver nanoparticles] in many human cell lines, and the short time limit of efficacy following infection, the Ag-NPs would likely make a more effective decontamination tool as opposed to an in vivo therapeutic agent. However, if the Ag-NPs do indeed facilitate the uptake of arenaviruses into the cell and inactivate the virus prior to cell entry, further studies should be performed to determine if Ag- NPs can prove to be an effective vaccine adjuvant.”

Speculative Studies and Clinical Use

These studies provide valuable insights into silve nanoparticle-virus interactions, and indicate that, with significantly more research, silver nanoparticles may have some role to play in preventing or managing infections. But the research does not support clinical applications at this stage.  Even if there was proof that silver nanoparticles are effective in humans in suppressing viral activity (and there is not), there are critical questions over dose and delivery.

To be effective, there would need to be systemic uptake of nano silver within the body at doses that are sufficient to inhibit the Ebola virus, but low enough to prevent unacceptable harm.  Currently, scientists have no ideas what an appropriate dose is.

Even if they did, it is not clear how the silver nanoparticles would be delivered.  Taking the material orally – as would be expected of colloidal silver dietary supplements – is unlikely to be effective as silver nanoparticles dissolve in gastric juices.  Nanoparticle uptake from the gut into the body is also very poor.  Inhaling silver nanoparticles is likewise unlikely to lead to significant nano-silver distribution through the body.  Which leaves direct injection of silver nanoparticles into the bloodstream – not an option to be undertaken lightly with an unproven and untested nanomaterial.

Given the commercial interests involved here and the paucity of evidence for nano-silver being in any way an appropriate treatment for Ebola, the wisdom of treating patients in Nigeria with the material has to be questioned on both medical and ethical grounds. There may be future treatments for infectious diseases that use nanoscale silver and other engineered nanomaterials.  But this does not seem the time to be cynically jumping on the Ebola bandwagon to promote products that may offer false hope, but little else.


Update August 16, 7:05 AM EST: It seems that the Lagos State Government has resolved not to use nano silver in the treatment of Ebola, but rather resolved to use ZMAPP. Source: The Daily Post

Andrew Maynard is Director of the Risk Science Center at the University of Michigan School of Public Health.
Print Email permalink (2) Comments (23945) Hits •  subscribe Share on facebook Stumble This submit to reddit submit to digg


Curcumin inhibits enveloped viruses like Ebola from spreading. High blood levels can be obtained with BCM-95 curcumin extract or something similar.

They should be trying Curcumin extract in high doses to lessen the mortality and speed recovery.

To not try something like silver when they are dying seems pointless to me.

YOUR COMMENT (IEET's comment policy)

Login or Register to post a comment.

Next entry: Singularity 1 on 1: The Curiosity Cycle

Previous entry: Enhancing Virtues: Positivity


RSSIEET Blog | email list | newsletter |
The IEET is a 501(c)3 non-profit, tax-exempt organization registered in the State of Connecticut in the United States.

East Coast Contact: Executive Director, Dr. James J. Hughes,
56 Daleville School Rd., Willington CT 06279 USA 
Email: director @     phone: 860-428-1837

West Coast Contact: Managing Director, Hank Pellissier
425 Moraga Avenue, Piedmont, CA 94611
Email: hank @